Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health
Sign in and complete your Funding Passport to see whether you qualify — a transparent, rule-based verdict, not a black box.
Sign InAbout this opportunity
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers.
Required documents
The official source lists no specific documents here — confirm requirements before applying.
Source & verification trail
- Official source
- U.S. Federal Government (Grants.gov) ↗
- First retrieved
- November 20, 2026
- Last verified
- November 20, 2026
- Content fingerprint
527f382e82e39ff8…